Table 1.

Clinicopathologic and molecular characteristics of patients and tumors by CIMP status

CharacteristicTotal (%)CIMP (%)CIMP+ (%)Pa
No. of patients9972 (72.7)27 (27.3)
Sex1.000
 Male55 (55.6)40 (55.6)15 (55.6)
 Female44 (44.4)32 (44.4)12 (44.4)0
Age at surgery0.247
 <7064 (64.6)49 (68.1)15 (55.6)
 ≥7035 (35.4)23 (31.9)12 (44.4)
Stage0.067b
 I (T1–2 N0 M0)8 (8.1)3 (4.2)5 (18.5)
 II (T3–4 N0 M0)21 (21.2)18 (25.0)3 (11.1)
 III (anyT N1-2 M0)64 (64.6)47 (65.3)17 (63.0)
 IV (anyT anyN M1)6 (6.1)4 (5.6)2 (7.4)
Tumor differentiation1.000
 Well/moderate55 (55.6)40 (55.6)15 (55.6)
 Poor44 (44.4)32 (44.4)12 (44.4)
Extent of resection1.000b
 R087 (87.9)63 (87.5)24 (88.9)
 R1/R212 (12.1)9 (12.5)3 (11.1)
Chemotherapy/radiotherapy0.448
 No38 (38.4)26 (36.1)12 (44.4)
 Yes61 (61.6)46 (63.9)15 (55.6)
MSI status0.011
 MSS79 (79.8)62 (86.1)17 (63.0)
 MSI20 (20.2)10 (13.9)10 (37.0)
KRAS0.114
 Wild-type67 (67.7)52 (72.2)15 (55.6)
 Mutated32 (32.3)20 (27.8)12 (44.4)
MLH1 methylation<0.001b
 U85 (85.9)70 (97.2)15 (55.6)
 M14 (14.1)2 (2.8)12 (44.4)

Abbreviations: U, unmethylated; M, methylated.

  • aCIMP versus CIMP+, χ2 test unless indicated otherwise.

  • bFisher exact test.